Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications

Pharmaceutical Research

Volumn 24, Issue 7, 2007, Pages 1227-1251

  Koepsell, Hermann ^a   Lips, Katrin ^b   Volk, Christopher ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Drug transporters; MATE1; OCT1; OCT2; OCT3; OCT6; OCTN1; OCTN2; Organic cation transport; Polyspecific transporters

Indexed keywords

ACEBUTOLOL; AMANTADINE; ATROPINE; BECLOMETASONE; BUDESONIDE; CEFEPIME; CEFOSELIS; CEFSULODIN; CIMETIDINE; CITALOPRAM; CLONIDINE; DIPHENHYDRAMINE; DISOPYRAMIDE; FAMOTIDINE; KETAMINE; LEVOFLOXACIN; LIDOCAINE; MEMANTINE; MEPYRAMINE; MIDAZOLAM; OFLOXACIN; ORGANIC CATION TRANSPORTER; PHENCYCLIDINE; PIPERPHENAMINE; PRAZOSIN; PROCAINAMIDE; QUINIDINE; RANITIDINE; UNINDEXED DRUG; VERAPAMIL;

BASOPHIL; BRAIN; CELLULAR DISTRIBUTION; DRUG ABSORPTION; DRUG ELIMINATION; DRUG TRANSPORT; EPITHELIUM CELL; GENE MUTATION; GENETIC POLYMORPHISM; HISTAMINE RELEASE; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; KIDNEY; LIVER; LUNG; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SMALL INTESTINE; TISSUE DISTRIBUTION; TRANSCYTOSIS; TUMOR;

ANIMALS; BINDING SITES; BIOPHARMACEUTICS; CATIONS; CLONING, MOLECULAR; DRUG INTERACTIONS; DRUG TOXICITY; HUMANS; MODELS, MOLECULAR; NEUROTRANSMITTER AGENTS; ORGANIC CATION TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 34249943356     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9254-z     Document Type: Review

References (234)

1. A. H. Schinkel and J. W. Jonker. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55:3-29 (2003).
2. H. Daniel and G. Kottra. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 447:610-618 (2004).
3. B. Hagenbuch and P. J. Meier. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447:653-665 (2004).
4. J. E. van Montfoort, B. Hagenbuch, G. M. M. Groothuis, H. Koepsell, P. J. Meier, and D. K. F. Meijer. Drug uptake systems in liver and kidney. Curr. Drug Metab. 4:185-211 (2003).
5. H. Koepsell and H. Endou. The SLC22 drug transporter family. Pflugers Arch. 447:666-676 (2004).
6. H. Koepsell, B. M. Schmitt, and V. Gorboulev. Organic cation transporters. Rev. Physiol. Biochem. Pharmacol. 150:36-90 (2003).
7. M. Otsuka, T. Matsumoto, R. Morimoto, S. Arioka, H. Omote, and Y. Moriyama. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. U.S.A. 102:17923-17928 (2005).
8. H. Koepsell. Organic cation transporters in intestine, kidney, liver, and brain. Annu. Rev. Physiol. 60:243-266 (1998).
9. H. Koepsell. Polyspecific organic cation transporters: their functions and interactions with drugs. TIPS 25:375-381 (2004).
10. S. H. Wright and W. H. Dantzler. Molecular and cellular physiology of renal organic cation and anion transport. Physiol. Rev. 84:987-1049 (2004).
11. M. J. Dresser, M. K. Leabman, and K. M. Giacomini. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci. 90:397-421 (2001).
12. S. S. Pao, I. T. Paulsen, and M. H. Saier, Jr. Major facilitator superfamily. Microbiol. Mol. Biol. Rev. 62:1-34 (1998).
13. D. Gründemann, V. Gorboulev, S. Gambaryan, M. Veyhl, and H. Koepsell. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549-552 (1994).
14. L. Zhang, M. J. Dresser, A. T. Gray, S. C. Yost, S. Terashita, and K. M. Giacomini. Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 51:913-921 (1997).
15. V. Gorboulev, J. C. Ulzheimer, A. Akhoundova, I. Ulzheimer-Teuber, U. Karbach, S. Quester, C. Baumann, F. Lang, A. E. Busch, and H. Koepsell. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16:871-881 (1997).
16. S. Terashita, M. J. Dresser, L. Zhang, A. T. Gray, S. C. Yost, and K. M. Giacomini. Molecular cloning and functional expression of a rabbit renal organic cation transporter. Biochim. Biophys. Acta 1369:1-6 (1998).
17. R. M. Green, K. Lo, C. Sterritt, and D. R. Beier. Cloning and functional expression of a mouse liver organic cation transporter. Hepatology 29:1556-1562 (1999).
18. M. Okuda, H. Saito, Y. Urakami, M. Takano, and K. Inui. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem. Biophys. Res. Commun. 224:500-507 (1996).
19. K. A. Mooslehner and N. D. Allen. Cloning of the mouse organic cation transporter 2 gene, Slc22a2, from an enhancer-trap transgene integration locus. Mamm. Genome 10:218-224 (1999).
20. 1 cells. J. Biol. Chem. 272:10408-10413 (1997).
21. D. Gründemann, B. Schechinger, G. A. Rappold, and E. Schömig. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat. Neurosci. 1:349-351 (1998).
22. R. Kekuda, P. D. Prasad, X. Wu, H. Wang, Y.-J. Fei, F. H. Leibach, and V. Ganapathy. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J. Biol. Chem. 273:15971-15979 (1998).
23. X. Wu, W. Huang, M. E. Ganapathy, H. Wang, R. Kekuda, S. J. Conway, F. H. Leibach, and V. Ganapathy. Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am. J. Physiol. Renal Physiol. 279:F449-F458 (2000).
24. L. Zhang, M. J. Dresser, J. K. Chun, P. C. Babbitt, and K. M. Giacomini. Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A). J. Biol. Chem. 272:16548-16554 (1997).
25. Y. Urakami, M. Akazawa, H. Saito, M. Okuda, and K.-I. Inui. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J. Am. Soc. Nephrol. 13:1703-1710 (2002).
26. M. R. Koehler, B. Wissinger, V. Gorboulev, H. Koepsell, and M. Schmid. The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26. Cytogenet. Cell Genet. 79:198-200 (1997).
27. D. Gründemann and E. Schömig. Gene structures of the human non-neuronal monoamine transporters EMT and OCT2. Hum. Genet. 106:627-635 (2000).
28. M. Hayer, H. Bönisch, and M. Bruss. Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1). Ann. Hum. Genet. 63:473-482 (1999).
29. S. Verhaagh, N. Schweifer, D. P. Barlow, and R. Zwart. Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics 55:209-218 (1999).
30. X. Wu, R. L. George, W. Huang, H. Wang, S. J. Conway, F. H. Leibach, and V. Ganapathy. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim. Biophys. Acta 1466:315-327 (2000).
31. I. Tamai, H. Yabuuchi, J. Nezu, Y. Sai, A. Oku, M. Shimane, and A. Tsuji. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett. 419:107-111 (1997).
32. I. Tamai, R. Ohashi, J. Nezu, Y. Sai, D. Kobayashi, A. Oku, M. Shimane, and A. Tsuji. Molecular and functional characterization of organic cation/carnitine transporter family in mice. J. Biol. Chem. 275:40064-40072 (2000).
33. X. Wu, P. D. Prasad, F. H. Leibach, and V. Ganapathy. cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem. Biophys. Res. Commun. 246:589-595 (1998).
34. T. Sekine, H. Kusuhara, N. Utsunomiya-Tate, M. Tsuda, Y. Sugiyama, Y. Kanai, and H. Endou. Molecular cloning and characterization of high-affinity carnitine transporter from rat intestine. Biochem. Biophys. Res. Commun. 251:586-591 (1998).
35. E. Schömig, F. Spitzenberger, M. Engelhardt, F. Martel, N. Örding, and D. Gründemann. Molecular cloning and characterization of two novel transport proteins from rat kidney. FEBS Lett. 425:79-86 (1998).
36. V. D. Peltekova, R. F. Wintle, L. A. Rubin, C. I. Amos, Q. Huang, X. Gu, B. Newman, M. Van Oene, D. Cescon, G. Greenberg, A. M. Griffiths, P. H. St. George-Hyslop, and K. A. Siminovitch. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat. Genet. 36:471-475 (2004).
37. A. Enomoto, M. F. Wempe, H. Tsuchida, H. J. Shin, S. H. Cha, N. Anzai, A. Goto, A. Sakamoto, T. Niwa, Y. Kanai, M. W. Anders, and H. Endou. Molecular identification of a novel carnitine transporter specific to human testis: Insights into the mechanism of carnitine recognition. J. Biol. Chem. 277:36262-36271 (2002).
38. S. Gong, X. Lu, Y. Xu, C. F. Swiderski, C. T. Jordan, and J. A. Moscow. Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp. Hematol. 30:1162-1169 (2002).
39. M. Hiasa, T. Matsumoto, T. Komatsu, and Y. Moriyama. Wide variety of locations for rodent MATE1, a transporter protein that mediates the final excretion step for toxic organic cations. Am. J. Physiol. Cell Physiol. 291:478-486 (2006).
40. T. Terada, S. Masuda, J.-i. Asaka, M. Tsuda, T. Katsura, and K.-i. Inui. Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm. Res. 23:1696-1701 (2006).
41. K. Y. Ohta, K. Inoue, Y. Hayashi, and H. Yuasa. Molecular identification and functional characterization of rat MATE1 as an organic cation/H+ antiporter in the kidney. Drug Metab. Dispos. 34:1868-1874 (2006).
42. S. Masuda, T. Terada, A. Yonezawa, Y. Tanihara, K. Kishimoto, T. Katsura, O. Ogawa, and K.-i. Inui. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 17:2127-2135 (2006).
43. J. J. Chen, Z. Li, H. Pan, D. L. Murphy, H. Tamir, H. Koepsell, and M. D. Gershon. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J. Neurosci. 21:6348-6361 (2001).
44. A. Schmitt, R. Mössner, A. Gossmann, I. G. Fischer, V. Gorboulev, D. L. Murphy, H. Koepsell, and K. P. Lesch. Organic cation transporter capable of transporting serotonin is up-regulated in serotonin transporter-deficient mice. J. Neurosci. Res. 71:701-709 (2003).
45. U. Karbach, J. Kricke, F. Meyer-Wentrup, V. Gorboulev, C. Volk, D. Loffing-Cueni, B. Kaissling, S. Bachmann, and H. Koepsell. Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am. J. Physiol. Renal Physiol. 279:F679-F687 (2000).
46. S. Choudhuri, N. J. Cherrington, N. Li, and C. D. Klaassen. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab. Dispos. 31:1337-1345 (2003).
47. K. S. Lips, C. Volk, B. M. Schmitt, U. Pfeil, P. Arndt, D. Miska, L. Ermert, W. Kummer, and H. Koepsell. Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am. J. Respir. Cell Mol. Biol. 33:79-88 (2005).
48. A. L. Slitt, N. J. Cherrington, D. P. Hartley, T. M. Leazer, and C. D. Klaassen. Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. Drug Metab. Dispos. 30:212-219 (2002).
49. Y. Alnouti, J. S. Petrick, and C. D. Klaassen. Tissue distribution and ontogeny of organic cation transporters in mice. Drug Metab. Dispos. 34:477-482 (2006).
50. J. Müller, K. S. Lips, L. Metzner, R. H. H. Neubert, H. Koepsell, and M. Brandsch. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem. Pharmacol. 70:1851-1860 (2005).
51. J. Alcorn, X. Lu, J. A. Moscow, and P. J. McNamara. Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J. Pharmacol. Exp. Ther. 303:487-496 (2002).
52. M. Hayer-Zillgen, M. Brüss, and H. Bönisch. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol. 136:829-836 (2002).
53. K. S. Lips, J. Wunsch, S. Zarghooni, T. Bschleipfer, K. Schukowski, W. Weidner, I. Wessler, U. Schwantes, H. Koepsell, and W. Kummer. Acetylcholine and molecular components of its synthesis and release machinery in the urothelium. Eur. Urol. PMID: 17084519 (2006).
54. M. R. Ballestero, M. J. Monte, O. Briz, F. Jimenez, F. Gonzalez-San Martin, and J. J. G. Marin. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem. Pharmacol. 72:729-738 (2006).
55. S. Zhang, K. S. Lovejoy, J. E. Shima, L. L. Lagpacan, Y. Shu, A. Lapuk, Y. Chen, T. Komori, J. W. Gray, X. Chen, S. J. Lippard, and K. M. Giacomini. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 66:8847-8857 (2006).
56. E. Beéry, P. Middel, A. Bahn, H. S. Willenberg, Y. Hagos, H. Koepsell, S. R. Bornstein, G. A. Müller, G. Burckhardt, and J. Steffgen. Molecular evidence of organic ion transporters in the rat adrenal cortex with adrenocorticotropin-regulated zonal expression. Endocrinology 144:4519-4526 (2003).
57. P. M. Gerk, C. Y. Oo, E. W. Paxton, J. A. Moscow, and P. J. McNamara. Interactions between cimetidine, nitrofurantoin, and probenecid active transport into rat milk. J. Pharmacol. Exp. Ther. 296:175-180 (2001).
58. E. Schneider, F. Machavoine, J.-M. Pléau, A.-F. Bertron, R. L. Thurmond, H. Ohtsu, T. Watanabe, A. H. Schinkel, and M. Dy. Organic cation transporter 3 modulates murine basophil functions by controlling intracellular histamine levels. J. Exp. Med. 202:387-393 (2005).
59. L. M. Augustine, R. J. Markelewicz, Jr., K. Boekelheide, and N. J. Cherrington. Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. Drug Metab. Dispos. 33:182-189 (2005).
60. F. Meyer-Wentrup, U. Karbach, V. Gorboulev, P. Arndt, and H. Koepsell. Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem. Biophys. Res. Commun. 248:673-678 (1998).
61. M. Sugawara-Yokoo, Y. Urakami, H. Koyama, K. Fujikura, S. Masuda, H. Saito, T. Naruse, K.-i. Inui, and K. Takata. Differential localization of organic cation transporters rOCT1 and rOCT2 in the basolateral membrane of rat kidney proximal tubules. Histochem. Cell Biol. 114:175-180 (2000).
62. W. Kummer, S. Wiegand, S. Akinci, I. Wessler, A. H. Schinkel, J. Wess, H. Koepsell, R. V. Haberberger, and K. S. Lips. Role of acetylcholine and polyspecific cation transporters in serotonin-induced bronchoconstriction in the mouse. Respir. Res. 7:65 (2006).
63. A. E. Busch, U. Karbach, D. Miska, V. Gorboulev, A. Akhoundova, C. Volk, P. Arndt, J. C. Ulzheimer, M. S. Sonders, C. Baumann, S. Waldegger, F. Lang, and H. Koepsell. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol. Pharmacol. 54:342-352 (1998).
64. D. H. Sweet, D. S. Miller, and J. B. Pritchard. Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J. Biol. Chem. 276:41611-41619 (2001).
65. H. Motohashi, Y. Sakurai, H. Saito, S. Masuda, Y. Urakami, M. Goto, A. Fukatsu, O. Ogawa, and K.- I. Inui. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 13:866-874 (2002).
66. A. Seithel, J. Karlsson, C. Hilgendorf, A. Björquist, and A. L. Ungell. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur. J. Pharm. Sci. 28:291-299 (2006).
67. D. Kristufek, W. Rudorfer, C. Pifl, and S. Huck. Organic cation transporter mRNA and function in the rat superior cervical ganglion. J. Physiol. 543:117-134 (2002).
68. T. Shang, A. V. Uihlein, J. Van Asten, B. Kalyanaraman, and C. J. Hillard. 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. J. Neurochem. 85:358-367 (2003).
69. M. Inazu, H. Takeda, and T. Matsumiya. Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes. J. Neurochem. 84:43-52 (2003).
70. C. Haag, R. Berkels, D. Gründemann, A. Lazar, D. Taubert, and E. Schömig. The localisation of the extraneuronal monoamine transporter (EMT) in rat brain. J. Neurochem. 88:291-297 (2004).
71. R. Sata, H. Ohtani, M. Tsujimoto, H. Murakami, N. Koyabu, T. Nakamura, T. Uchiumi, M. Kuwano, H. Nagata, K. Tsukimori, H. Nakano, and Y. Sawada. Functional analysis of organic cation transporter 3 expressed in human placenta. J. Pharmacol. Exp. Ther. 315:888-895 (2005).
72. X. Wu, R. Kekuda, W. Huang, Y.-J. Fei, F. H. Leibach, J. Chen, S. J. Conway, and V. Ganapathy. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J. Biol. Chem. 273:32776-32786 (1998).
73. P. J. Gasser, C. A. Lowry, and M. Orchinik. Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J. Neurosci. 26:8758-8766 (2006).
74. V. Vialou, A. Amphoux, R. Zwart, B. Giros, and S. Gautron. Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J. Neurosci. 24:2846-2851 (2004).
75. S. Tokuhiro, R. Yamada, X. Chang, A. Suzuki, Y. Kochi, T. Sawada, M. Suzuki, M. Nagasaki, M. Ohtsuki, M. Ono, H. Furukawa, M. Nagashima, S. Yoshino, A. Mabuchi, A. Sekine, S. Saito, A. Takahashi, T. Tsunoda, Y. Nakamura, and K. Yamamoto. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat. Genet. 35:341-348 (2003).
76. W. Xuan, A.-M. Lamhonwah, C. Librach, K. Jarvi, and I. Tein. Characterization of organic cation/carnitine transporter family in human sperm. Biochem. Biophys. Res. Commun. 306:121-128 (2003).
77. A.-M. Lamhonwah and I. Tein. Novel localization of OCTN1, an organic cation/carnitine transporter, to mammalian mitochondria. Biochem. Biophys. Res. Commun. 345:1315-1325 (2006).
78. A.-M. Lamhonwah, C. Ackerley, R. Onizuka, A. Tilups, D. Lamhonwah, C. Chung, K. S. Tao, R. Tellier, and I. Tein. Epitope shared by functional variant of organic cation/carnitine transporter, OCTN1, Campylobacter jejuni and Mycobacterium paratuberculosis may underlie susceptibility to Crohn's disease at 5q31. Biochem. Biophys. Res. Commun. 337:1165-1175 (2005).
79. I. Tamai, T. Nakanishi, D. Kobayashi, K. China, Y. Kosugi, J.-i. Nezu, Y. Sai, and A. Tsuji. Involvement of OCTN1 (SLC22A4) in pH-dependent transport of organic cations. Mol. Pharm. 1:57-66 (2004).
80. I. Tamai, R. Ohashi, J. Nezu, H. Yabuuchi, A. Oku, M. Shimane, Y. Sai, and A. Tsuji. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J. Biol. Chem. 273:20378-20382 (1998).
81. T. Terada, Y. Shimada, X. Pan, K. Kishimoto, T. Sakurai, R. Doi, H. Onodera, T. Katsura, M. Imamura, and K.-i. Inui. Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. Biochem. Pharmacol. 70:1756-1763 (2005).
82. M. Inazu, H. Takeda, K. Maehara, K. Miyashita, A. Tomoda, and T. Matsumiya. Functional expression of the organic cation/carnitine transporter 2 in rat astrocytes. J. Neurochem. 97:424-434 (2006).
83. I. Tamai, K. China, Y. Sai, D. Kobayashi, J.-i. Nezu, E. Kawahara, and A. Tsuji. Na+-coupled transport of L-carnitine via high-affinity carnitine transporter OCTN2 and its subcellular localization in kidney. Biochim. Biophys. Acta 1512:273-284 (2001).
84. K. Yakushiji, S. Kai, M. Yamauchi, M. Kuwajima, Y. Osada, and K. Toshimori. Expression and distribution of OCTN2 in mouse epididymis and its association with obstructive azoospermia in juvenile visceral steatosis mice. Int. J. Urol. 13:420-426 (2006).
85. J. M. Durán, M. J. Peral, M. L. Calonge, and A. A. Ilundáin. OCTN3: A Na+-independent L-carnitine transporter in enterocytes basolateral membrane. J. Cell. Physiol. 202:929-935 (2005).
86. A.-M. Lamhonwah, J. Skaug, S. W. Scherer, and I. Tein. A third human carnitine/organic cation transporter (OCTN3) as a candidate for the 5q31 Crohn's disease locus (IBD5). Biochem. Biophys. Res. Commun. 301:98-101 (2003).
87. M. Okabe, M. Unno, H. Harigae, M. Kaku, Y. Okitsu, T. Sasaki, T. Mizoi, K. Shiiba, H. Takanaga, T. Terasaki, S. Matsuno, I. Sasaki, S. Ito, and T. Abe. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun. 333:754-762 (2005).
88. B. M. Schmitt and H. Koepsell. Alkali cation binding and permeation in the rat organic cation transporter rOCT2. J. Biol. Chem. 280:24481-24490 (2005).
89. M. Okuda, Y. Urakami, H. Saito, and K.-i. Inui. Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim. Biophys. Acta 1417:224-231 (1999).
90. P. Arndt, C. Volk, V. Gorboulev, T. Budiman, C. Popp, I. Ulzheimer-Teuber, A. Akhoundova, S. Koppatz, E. Bamberg, G. Nagel, and H. Koepsell. Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am. J. Physiol. Renal Physiol. 281:F454-F468 (2001).
91. G. Nagel, C. Volk, T. Friedrich, J. C. Ulzheimer, E. Bamberg, and H. Koepsell. A reevaluation of substrate specificity of the rat cation transporter rOCT1. J. Biol. Chem. 272:31953-31956 (1997).
92. A. E. Busch, S. Quester, J. C. Ulzheimer, S. Waldegger, V. Gorboulev, P. Arndt, F. Lang, and H. Koepsell. Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J. Biol. Chem. 271:32599-32604 (1996).
93. M. J. Dresser, A. T. Gray, and K. M. Giacomini. Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J. Pharmacol. Exp. Ther. 292:1146-1152 (2000).
94. T. Keller, M. Elfeber, V. Gorboulev, H. Reiländer, and H. Koepsell. Purification and functional reconstitution of the rat organic cation transporter OCT1. Biochemistry 44:12253-12263 (2005).
95. H. Kimura, M. Takeda, S. Narikawa, A. Enomoto, K. Ichida, and H. Endou. Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J. Pharmacol. Exp. Ther. 301:293-298 (2002).
96. S. Harlfinger, C. Fork, A. Lazar, E. Schömig, and D. Gründemann. Are organic cation transporters capable of transporting prostaglandins? Naunyn-Schmiedeberg's Arch. Pharmacol. 372:125-130 (2005).
97. C. Volk, V. Gorboulev, T. Budiman, G. Nagel, and H. Koepsell. Different affinities of inhibitors to the outwardly and inwardly directed substrate binding site of organic cation transporter 2. Mol. Pharmacol. 64:1037-1047 (2003).
98. T. Budiman, E. Bamberg, H. Koepsell, and G. Nagel. Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat. J. Biol. Chem. 275:29413-29420 (2000).
99. R. Ohashi, I. Tamai, H. Yabuuchi, J. -i Nezu, A. Oku, Y. Sai, M. Shimane, and A. Tsuji. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J. Pharmacol. Exp. Ther. 291:778-784 (1999).
100. X. Wu, W. Huang, P. D. Prasad, P. Seth, D. P. Rajan, F. H. Leibach, J. Chen, S. J. Conway, and V. Ganapathy. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J. Pharmacol. Exp. Ther. 290:1482-1492 (1999).
101. C. A. Wagner, U. Lükewille, S. Kaltenbach, I. Moschen, A. Bröer, T. Risler, S. Bröer, and F. Lang. Functional and pharmacological characterization of the human Na+/carnitine cotransporter hOCTN2. Am. J. Physiol. Renal Physiol. 279:F584-F591 (2000).
102. H. Yabuuchi, I. Tamai, J. Nezu, K. Sakamoto, A. Oku, M. Shimane, Y. Sai, and A. Tsuji. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J. Pharmacol. Exp. Ther. 289:768-773 (1999).
103. W. M. Suhre, S. Ekins, C. Chang, P. W. Swaan, and S. H. Wright. Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol. Pharmacol. 67:1067-1077 (2005).
104. D. Gründemann, G. Liebich, N. Kiefer, S. Köster, and E. Schömig. Selective substrates for non-neuronal monoamine transporters. Mol. Pharmacol. 56:1-10 (1999).
105. A. Amphoux, V. Vialou, E. Drescher, M. Brüss, C. M. La Cour, C. Rochat, M. J. Millan, B. Giros, H. Bönisch, and S. Gautron. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50:941-952 (2006).
106. D. Gründemann, S. Köster, N. Kiefer, T. Breidert, M. Engelhardt, F. Spitzenberger, N. Obermüller, and E. Schömig. Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J. Biol. Chem. 273:30915-30920 (1998).
107. L. Zhang, M. E. Schaner, and K. M. Giacomini. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J. Pharmacol. Exp. Ther. 286:354-361 (1998).
108. D. Gründemann, S. Harlfinger, S. Golz, A. Geerts, A. Lazar, R. Berkels, N. Jung, A. Rubbert, and E. Schömig. Discovery of the ergothioneine transporter. Proc. Natl. Acad. Sci. U. S. A. 102:5256-5261 (2005).
109. H. Tahara, H. Kusuhara, H. Endou, H. Koepsell, T. Imaoka, E. Fuse, and Y. Sugiyama. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther. 315:337-345 (2005).
110. M. E. Ganapathy, W. Huang, D. P. Rajan, A. L. Carter, M. Sugawara, K. Iseki, F. H. Leibach, and V. Ganapathy. b-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J. Biol. Chem. 275:1699-1707 (2000).
111. M. Takeda, S. Khamdang, S. Narikawa, H. Kimura, Y. Kobayashi, T. Yamamoto, S. H. Cha, T. Sekine, and H. Endou. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther. 300:918-924 (2002).
112. N. Kimura, S. Masuda, Y. Tanihara, H. Ueo, M. Okuda, T. Katsura, and K.-I. Inui. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet. 20:379-386 (2005).
113. L. Zhang, W. Gorset, C. B. Washington, T. F. Blaschke, D. L. Kroetz, and K. M. Giacomini. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab. Dispos. 28:329-334 (2000).
114. G. Ciarimboli, T. Ludwig, D. Lang, H. Pavenstädt, H. Koepsell, H.-J. Piechota, J. Haier, U. Jaehde, J. Zisowsky, and E. Schlatter. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 167:1477-1484 (2005).
115. Q. Li, Y. Sai, Y. Kato, H. Muraoka, I. Tamai, and A. Tsuji. Transporter-mediated renal handling of nafamostat mesilate. J. Pharm. Sci. 93:262-272 (2004).
116. D. Gründemann, C. Hahne, R. Berkels, and E. Schömig. Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2). J. Pharmacol. Exp. Ther. 304:810-817 (2003).
117. R. Ohashi, I. Tamai, A. Inano, M. Katsura, Y. Sai, J.-I. Nezu, and A. Tsuji. Studies on functional sites of organic cation/carnitine transporter OCTN2 (SLC22A5) using a Ser467Cys mutant protein. J. Pharmacol. Exp. Ther. 302:1286-1294 (2002).
118. M. J. Dresser, G. Xiao, M. K. Leabman, A. T. Gray, and K. M. Giacomini. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm. Res. 19:1244-1247 (2002).
119. A. E. Busch, S. Quester, J. C. Ulzheimer, V. Gorboulev, A. Akhoundova, S. Waldegger, F. Lang, and H. Koepsell. Monoamine neurotransmitter transport mediated by the polyspecific cation transporter rOCT1. FEBS Lett. 395:153-156 (1996).
120. M. Kakehi, N. Koyabu, T. Nakamura, T. Uchiumi, M. Kuwano, H. Ohtani, and Y. Sawada. Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochem. Biophys. Res. Commun. 296:644-650 (2002).
121. R. Ohashi, I. Tamai, J.-I. Nezu, H. Nikaido, N. Hashimoto, A. Oku, Y. Sai, M. Shimane, and A. Tsuji. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol. Pharmacol. 59:358-366 (2001).
122. A. Inano, Y. Sai, Y. Kato, I. Tamai, M. Ishiguro, and A. Tsuji. Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition. Drug Metab. Pharmacokinet. 19:180-189 (2004).
123. P. Seth, X. Wu, W. Huang, F. H. Leibach, and V. Ganapathy. Mutations in novel organic cation transporter (OCTN2), an organic cation/carnitine transporter, with differential effects on the organic cation transport function and the carnitine transport function. J. Biol. Chem. 274:33388-33392 (1999).
124. S. Berardi, B. Stieger, B. Hagenbuch, E. Carafoli, and S. Krähenbühl. Characterization of L-carnitine transport into rat skeletal muscle plasma membrane vesicles. Eur. J. Biochem. 267:1985-1994 (2000).
125. B. Stieger, B. O'Neill, and S. Krähenbühl. Characterization of L-carnitine transport by rat kidney brush-border-membrane vesicles. Biochem. J. 309:643-647 (1995).
126. C. J. Rebouche and D. L. Mack. Sodium gradient-stimulated transport of L-carnitine into renal brush border membrane vesicles: kinetics, specificity, and regulation by dietary carnitine. Arch. Biochem. Biophys. 235:393-402 (1984).
127. G. Ciarimboli, K. Struwe, P. Arndt, V. Gorboulev, H. Koepsell, E. Schlatter, and J. R. Hirsch. Regulation of the human organic cation transporter hOCT1. J. Cell. Physiol. 201:420-428 (2004).
128. T. Mehrens, S. Lelleck, I. Çetinkaya, M. Knollmann, H. Hohage, V. Gorboulev, P. Bokník, H. Koepsell, and E. Schlatter. The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependent phosphorylation. J. Am. Soc. Nephrol. 11:1216-1224 (2000).
129. G. Ciarimboli, H. Koepsell, M. Iordanova, V. Gorboulev, B. Dürner, D. Lang, B. Edemir, R. Schröter, T. Van Le, and E. Schlatter. Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J. Am. Soc. Nephrol. 16:1562-1570 (2005).
130. I. Çetinkaya, G. Ciarimboli, G. Yalcinkaya, T. Mehrens, A. Velic, J. R. Hirsch, V. Gorboulev, H. Koepsell, and E. Schlatter. Regulation of human organic cation transporter hOCT2 by PKA, PI3K, and calmodulin-dependent kinases. Am. J. Physiol. Renal Physiol. 284:F293-F302 (2003).
131. F. Martel, E. Keating, C. Calhau, D. Gründemann, E. Schömig, and I. Azevedo. Regulation of human extraneuronal monoamine transporter (hEMT) expressed in HEK293 cells by intracellular second messenger systems. Naunyn Schmiedeberg's Arch. Pharmacol. 364:487-495 (2001).
132. G. Pietig, T. Mehrens, J. R. Hirsch, I. Çetinkaya, H. Piechota, and E. Schlatter. Properties and regulation of organic cation transport in freshly isolated human proximal tubules. J. Biol. Chem. 276:33741-33746 (2001).
133. Y. Kato, K. Yoshida, C. Watanabe, Y. Sai, and A. Tsuji. Screening of the interaction between xenobiotic transporters and PDZ proteins. Pharm. Res. 21:1886-1894 (2004).
134. Y. Kato, Y. Sai, K. Yoshida, C. Watanabe, T. Hirata, and A. Tsuji. PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2. Mol. Pharmacol. 67:734-743 (2005).
135. E. Schlatter, V. Mönnich, I. Çetinkaya, T. Mehrens, G. Ciarimboli, J. R. Hirsch, C. Popp, and H. Koepsell. The organic cation transporters rOCT1 and hOCT2 are inhibited by cGMP. J. Membr. Biol. 189:237-244 (2002).
136. H. M. Bowman and J. B. Hook. Sex differences in organic ion transport by rat kidney. Proc. Soc. Exp. Biol. Med. 141:258-262 (1972).
137. Y. Urakami, N. Nakamura, K. Takahashi, M. Okuda, H. Saito, Y. Hashimoto, and K.-i. Inui. Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett. 461:339-342 (1999).
138. Y. Urakami, M. Okuda, H. Saito, and K.-i. Inui. Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Lett. 473:173-176 (2000).
139. Y. Shu, C. L. Bello, L. M. Mangravite, B. Feng, and K. M. Giacomini. Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in madin-darby canine kidney cells. J. Pharmacol. Exp. Ther. 299:392-398 (2001).
140. J.-i. Asaka, T. Terada, M. Okuda, T. Katsura, and K.-i. Inui. Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3. Pharm. Res. 1-8 (2006).
141. C. E. Groves, W. B. Suhre, N. J. Cherrington, and S. H. Wright. Sex differences in the mRNA, protein, and functional expression of organic anion transporter (Oat) 1, Oat3, and organic cation transporter (Oct) 2 in rabbit renal proximal tubules. J. Pharmacol. Exp. Ther. 316:743-752 (2006).
142. M. Saborowski, G. A. Kullak-Ublick, and J. J. Eloranta. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4a. J. Pharmacol. Exp. Ther. 317:778-785 (2006).
143. W. Nie, S. Sweetser, M. Rinella, and R. M. Green. Transcriptional regulation of murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor-a and -g. Am. J. Physiol. Gastrointest. Liver Physiol. 288:G207-G212 (2005).
144. L. Ji, S. Masuda, H. Saito, and K.-I. Inui. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int. 62:514-524 (2002).
145. M. C. Thomas, C. Tikellis, W. C. Burns, V. Thallas, J. M. Forbes, Z. Cao, T. M. Osicka, L. M. Russo, G. Jerums, H. Ghabrial, M. E. Cooper, and P. Kantharidis. Reduced tubular cation transport in diabetes: Prevented by ACE inhibition. Kidney Int. 63:2152-2161 (2003).
146. M. C. Thomas, C. Tikellis, P. Kantharidis, W. C. Burns, M. E. Cooper, and J. M. Forbes. The role of advanced glycation in reduced organic cation transport associated with experimental diabetes. J. Pharmacol. Exp. Ther. 311:456-466 (2004).
147. B. Grover, C. Auberger, R. Sarangarajan, and W. Cacini. Functional impairment of renal organic cation transport in experimental diabetes. Pharmacol. Toxicol. 90:181-186 (2002).
148. Y. Habu, I. Yano, A. Takeuchi, H. Saito, M. Okuda, A. Fukatsu, and K.-i. Inui. Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1, rOAT3 and rOCT2. Biochem. Pharmacol. 66:1107-1114 (2003).
149. G. U. Denk, C. J. Soroka, A. Mennone, H. Koepsell, U. Beuers, and J. L. Boyer. Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. Hepatology 39:1382-1389 (2004).
150. N. J. Cherrington, A. L. Slitt, N. Li, and C. D. Klaassen. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab. Dispos. 32:734-741 (2004).
151. K. Kitaichi, Y. Morishita, Y. Doi, J. Ueyama, M. Matsushima, Y.-L. Zhao, K. Takagi, and T. Hasegawa. Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats. Eur. J. Pharmacol. 464:39-48 (2003).
152. T. Maeda, M. Hirayama, D. Kobayashi, and I. Tamai. Regulation of testis-specific carnitine transporter (octn3) gene by proximal cis-acting elements Sp1 in mice. Biochem. Pharmacol. 70:858-868 (2005).
153. O. Dransfeld, T. Gehrmann, K. Köhrer, G. Kircheis, C. Holneicher, D. Häussinger, and M. Wettstein. Oligonucleotide microarray analysis of differential transporter regulation in the regenerating rat liver. Liver Int. 25:1243-1258 (2005).
154. J. W. Jonker, E. Wagenaar, C. A. A. M. Mol, M. Buitelaar, H. Koepsell, J. W. Smit, and A. H. Schinkel. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (oct1[Slc22a1]) gene. Mol. Cell. Biol. 21:5471-5477 (2001).
155. R. Zwart, S. Verhaagh, M. Buitelaar, C. Popp-Snijders, and D. P. Barlow. Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol. Cell Biol. 21:4188-4196 (2001).
156. J. W. Jonker, E. Wagenaar, S. van Eijl, and A. H. Schinkel. Deficiency in the organic cation transporters 1 and 2 (oct1/oct2 [slc22a1/slc22a2]) in mice abolishes renal secretion of organic cations. Mol. Cell Biol. 23:7902-7908 (2003).
157. D.-S. Wang, J. W. Jonker, Y. Kato, H. Kusuhara, A. H. Schinkel, and Y. Sugiyama. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 302:510-515 (2002).
158. K. Yokogawa, M. Yonekawa, I. Tamai, R. Ohashi, Y. Tatsumi, Y. Higashi, M. Nomura, N. Hashimoto, H. Nikaido, J. Hayakawa, J. Nezu, A. Oku, M. Shimane, K. Miyamoto, and A. Tsuji. Loss of wild-type carrier-mediated L-carnitine transport activity in hepatocytes of juvenile visceral steatosis mice. Hepatology 30:997-1001 (1999).
159. K.-m. Lu, H. Nishimori, Y. Nakamura, K. Shima, and M. Kuwajima. A missense mutation of mouse OCTN2, a sodium-dependent carnitine cotransporter, in the juvenile visceral steatosis mouse. Biochem. Biophys. Res. Commun. 252:590-594 (1998).
160. N. Hashimoto, F. Suzuki, I. Tamai, H. Nikaido, M. Kuwajima, J.-I. Hayakawa, and A. Tsuji. Gene-dose effect on carnitine transport activity in embryonic fibroblasts of JVS mice as a model of human carnitine transporter deficiency. Biochem. Pharmac. 55:1729-1732 (1998).
161. J. Hayakawa, T. Koizumi, and H. Nikaido. Inheritance of juvenile visceral steatosis found in C3H-H-2o mice. Mouse Genome 86:261 (1990).
162. T. Koizumi, H. Nikaido, J. Hayakawa, A. Nonomura, and T. Yoneda. Infantile disease with microvesicular fatty infiltration of viscera spontaneously occurring in the C3H-H-2° strain of mouse with similarities to Reye's syndrome. Lab. Anim. 22:83-87 (1988).
163. M. Horiuchi, H. Yoshida, K. Kobayashi, K. Kuriwaki, K. Yoshimine, M. Tomomura, T. Koizumi, H. Nikaido, J. Hayakawa, M. Kuwajima, and T. Saheki. Cardiac hypertrophy in juvenile visceral steatosis (jvs) mice with systemic carnitine deficiency. FEBS Lett. 326:267-271 (1993).
164. M. Tomomura, Y. Imamura, M. Horiuchi, T. Koizumi, H. Nikaido, J. Hayakawa, and T. Saheki. Abnormal expression of urea cycle enzyme genes in juvenile visceral steatosis (jvs) mice. Biochim. Biophys. Acta 1138:167-171 (1992).
165. K. Toshimori, M. Kuwajima, K. Yoshinaga, T. Wakayama, and K. Shima. Dysfunctions of the epididymis as a result of primary carnitine deficiency in juvenile visceral steatosis mice. FEBS Lett. 446:323-326 (1999).
166. R. Kerb, U. Brinkmann, N. Chatskaia, D. Gorbunov, V. Gorboulev, E. Mornhinweg, A. Keil, M. Eichelbaum, and H. Koepsell. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12:591-595 (2002).
167. Y. Shu, M. K. Leabman, B. Feng, L. M. Mangravite, C. C. Huang, D. Stryke, M. Kawamoto, S. J. Johns, J. DeYoung, E. Carlson, T. E. Ferrin, I. Herskowitz, and K. M. Giacomini, Pharmacogenetics of membrane transporters investigators. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl. Acad. Sci.U.S.A. 100:5902-5907 (2003).
168. M. Itoda, Y. Saito, K. Maekawa, H. Hichiya, K. Komamura, S. Kamakura, M. Kitakaze, H. Tomoike, K. Ueno, S. Ozawa, and J.-i. Sawada. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab. Pharmacokinet. 19:308-312 (2004).
169. H. Fukushima-Uesaka, K. Maekawa, S. Ozawa, K. Komamura, K. Ueno, M. Shibakawa, S. Kamakura, M. Kitakaze, H. Tomoike, Y. Saito, and J. Sawada. Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab. Pharmacokin. 19:239-244 (2004).
170. M. K. Leabman, C. C. Huang, M. Kawamoto, S. J. Johns, D. Stryke, T. E. Ferrin, J. DeYoung, T. Taylor, A. G. Clark, I. Herskowitz, and K. M. Giacomini. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12:395-405 (2002).
171. T. Fujita, T. J. Urban, M. K. Leabman, K. Fujita, and K. M. Giacomini. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J. Pharm. Sci. 95:25-36 (2006).
172. A. Takeuchi, H. Motohashi, M. Okuda, and K.-i. Inui. Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1. Drug Metab. Pharmacokin. 18:409-412 (2003).
173. T. Sakata, N. Anzai, H. J. Shin, R. Noshiro, T. Hirata, H. Yokoyama, Y. Kanai, and H. Endou. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem. Biophys. Res. Commun. 313:789-793 (2004).
174. A. Koizumi, J.-i. Nozaki, T. Ohura, T. Kayo, Y. Wada, J.-i. Nezu, R. Ohashi, I. Tamai, Y. Shoji, G. Takada, S. Kibira, T. Matsuishi, and A. Tsuji. Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. Hum. Mol. Genet. 8:2247-2254 (1999).
175. N. L. S. Tang, V. Ganapathy, X. Wu, J. Hui, P. Seth, P. M. P. Yuen, T. F. Fok, and N. M. Hjelm. Mutations of OCTN2, an organic cation/carnitine transporter, lead to deficient cellular carnitine uptake in primary carnitine deficiency. Hum. Mol. Genet. 8:655-660 (1999).
176. Y. Wang, J. Ye, V. Ganapathy, and N. Longo. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc. Natl. Acad. Sci. U.S.A. 96:2356-2360 (1999).
177. O. Palmieri, A. Latiano, R. Valvano, R. D'Inca, M. Vecchi, G. C. Sturniolo, S. Saibeni, F. Peyvandi, F. Bossa, C. Zagaria, A. Andriulli, M. Devoto, and V. Annese. Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Aliment. Pharmacol. Ther. 23:497-506 (2006).
178. J. D. Rioux, M. J. Daly, M. S. Silverberg, K. Lindblad, H. Steinhart, Z. Cohen, T. Delmonte, K. Kocher, K. Miller, S. Guschwan, E. J. Kulbokas, S. O'Leary, E. Winchester, K. Dewar, T. Green, V. Stone, C. Chow, A. Cohen, D. Langelier, G. Lapointe, D. Gaudet, J. Faith, N. Branco, S. B. Bull, R. S. McLeod, A. M. Griffiths, A. Bitton, G. R. Greenberg, E. S. Lander, K. A. Siminovitch, and T. J. Hudson. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat. Genet. 29:223-228 (2001).
179. M. S. Silverberg. OCTNs: Will the real IBD5 gene please stand up? World J. Gastroenterol. 12:3678-3681 (2006).
180. R. K. Russell, H. Drummond, E. Nimmo, N. Anderson, C. Noble, D. Wilson, P. Gillett, P. McGrogan, K. Hassan, L. Weaver, M. Bisset, G. Mahdi, and J. Satsangi. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth parameters in early-onset inflammatory bowel disease. Gut (2006).
181. A. Lazar, T. Zimmermann, W. Koch, D. Gründemann, A. Schömig, A. Kastrati, and E. Schömig. Lower prevalence of the OCT2 Ser270 allele in patients with essential hypertension. Clin. Exp. Hypertens. 28:645-653 (2006).
182. N. Aoyama, N. Takahashi, K. Kitaichi, R. Ishihara, S. Saito, N. Maeno, X. Ji, K. Takagi, Y. Sekine, M. Iyo, M. Harano, T. Komiyama, M. Yamada, I. Sora, H. Ujike, N. Iwata, T. Inada, and N. Ozaki. Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin. Exp. Res. 30:1644-1649 (2006).
183. D. Taubert, G. Grimberg, N. Jung, A. Rubbert, and E. Schömig. Functional role of the 503F variant of the organic cation transporter OCTN1 in Crohn's disease. Gut 54:1505-1506 (2005).
184. D. Taubert, A. Lazar, G. Grimberg, N. Jung, A. Rubbert, K.-S. Delank, A. Perniok, E. Erdmann, and E. Schömig. Association of rheumatoid arthritis with ergothioneine levels in red blood cells: a case control study. J. Rheumatol. 33:2139-2145 (2006).
185. S. Vermeire and P. Rutgeerts. Current status of genetics research in inflammatory bowel disease. Genes Immun. 6:637-645 (2005).
186. J. L. Santiago, A. Martinez, H. de la Calle, M. Fernandez-Arquero, M. A. Figueredo, E. G. de la Concha, and E. Urcelay. Evidence for the association of the SLC22A4 and SLC22A5 genes with Type 1 Diabetes: a case control study, BMC. Med. Genet. 7:54 (2006).
187. C. A. Stanley, S. DeLeeuw, P. M. Coates, C. Vianey-Liaud, P. Divry, J. P. Bonnefont, J. M. Saudubray, M. Haymond, F. K. Trefz, and G. N. Breningstall. Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann. Neurol. 30:709-716 (1991).
188. T. J. Urban, R. C. Gallagher, C. Brown, R. A. Castro, L. L. Lagpacan, C. M. Brett, T. R. Taylor, E. J. Carlson, T. E. Ferrin, E. G. Burchard, S. Packman, and K. M. Giacomini. Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). Mol. Pharmacol. 70:1602-1611 (2006).
189. C. Popp, V. Gorboulev, T. D. Müller, D. Gorbunov, N. Shatskaya, and H. Koepsell. Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol. Pharmacol. 67:1600-1611 (2005).
190. V. Gorboulev, N. Shatskaya, C. Volk, and H. Koepsell. Subtype-specific affinity for corticosterone of rat organic cation transporters rOCT1 and rOCT2 depends on three amino acids within the substrate binding region. Mol. Pharmacol. 67:1612-1619 (2005).
191. V. Gorboulev, C. Volk, P. Arndt, A. Akhoundova, and H. Koepsell. Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate. Mol. Pharmacol. 56:1254-1261 (1999).
192. X. Zhang, N. V. Shirahatti, D. Mahadevan, and S. H. Wright. A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2). J. Biol. Chem. 280:34813-34822 (2005).
193. J. Abramson, I. Smirnova, V. Kasho, G. Verner, H. R. Kaback, and S. Iwata. Structure and mechanism of the lactose permease of Escherichia coli. Science 301:610-615 (2003).
194. Y. Huang, M. J. Lemieux, J. Song, M. Auer, and D.-N. Wang. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 301:616-620 (2003).
195. R. M. Pelis, X. Zhang, Y. Danqprapai, and S. H. Wright. Cysteine accessibility in the hydrophilic cleft of the human organic cation transporter 2. J. Biol. Chem. 281:35272-35280 (2006).
196. Y. Wang, S. H. Korman, J. Ye, J. J. Gargus, A. Gutman, F. Taroni, B. Garavaglia, and N. Longo. Phenotype and genotype variation in primary carnitine deficiency. Genet. Med. 3:387-392 (2001).
197. Y. Wang, F. Taroni, B. Garavaglia, and N. Longo. Functional analysis of mutations in the OCTN2 transporter causing primary carnitine deficiency: lack of genotype-phenotype correlation. Hum. Mutat. 16:401-407 (2000).
198. A.-M. Lamhonwah, S. E. Olpin, R. J. Pollitt, C. Vianey-Saban, P. Divry, N. Guffon, G. T. N. Besley, R. Onizuka, L. J. De Meirleir, L. Cvitanovic-Sojat, I. Baric, C. Dionisi-Vici, K. Fumic, M. Maradin, and I. Tein. Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy. Am. J. Med. Genet. 111:271-284 (2002).
199. B. Burwinkel, J. Kreuder, S. Schweitzer, M. Vorgerd, K. Gempel, K.-D. Gerbitz, and M. W. Kilimann. Carnitine transporter OCTN2 mutations in systemic primary carnitine deficiency: a novel Arg169Gln mutation and a recurrent Arg282ter mutation associated with an unconventional splicing abnormality. Biochem. Biophys. Res. Commun. 261:484-487 (1999).
200. F. M. Vaz, H. R. Scholte, J. Ruiter, L. M. Hussaarts-Odijk, R. R. Pereira, S. Schweitzer, J. B. C. de Klerk, H. R. Waterham, and R. J. A. Wanders. Identification of two novel mutations in OCTN2 of three patients with systemic carnitine deficiency. Hum. Genet. 105:157-161 (1999).
201. E. Mayatepek, J. Nezu, I. Tamai, A. Oku, M. Katsura, M. Shimane, and A. Tsuji. Two novel missense mutations of the OCTN2 gene (W283R and V446F) in a patient with primary systemic carnitine deficiency. Hum. Mutat. 15:118 (2000).
202. Y. Wang, M. A. Kelly, T. M. Cowan, and N. Longo. A missense mutation in the OCTN2 gene associated with residual carnitine transport activity. Hum. Mutat. 15:238-245 (2000).
203. Y. Wang, T. A. Meadows, and N. Longo. Abnormal sodium stimulation of carnitine transport in primary carnitine deficiency. J. Biol. Chem. 275:20782-20786 (2000).
204. K. Turnheim and F. O. Lauterbach. Absorption and secretion of monoquaternary ammonium compounds by the isolated intestinal mucosa. Biochem. Pharmac. 26:99-108 (1977).
205. K. Turnheim and F. Lauterbach. Interaction between intestinal absorption and secretion of monoquaternary ammonium compounds in guinea pigs-a concept for the absorption kinetics of organic cations. J. Pharmacol. Exp. Ther. 212:418-424 (1980).
206. M. K. Kim and C.-K. Shim. The transport of organic cations in the small intestine: current knowledge and emerging concepts. Arch. Pharm. Res. 29:605-616 (2006).
207. S. Hsing, Z. Gatmaitan, and I. M. Arias. The function of Gp170, the multidrug-restistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 102:879-885 (1992).
208. F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84:7735-7738 (1987).
209. J. E. Van Montfoort, M. Müller, G. M. M. Groothuis, D. K. F. Meijer, H. Koepsell, and P. J. Meier. Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J. Pharmacol. Exp. Ther. 298:110-115 (2001).
210. M. Acara and B. Rennick. Regulation of plasma choline by the renal tubule: bidirectional transport of choline. Am. J. Physiol. 225:1123-1128 (1973).
211. K. Besseghir, L. B. Pearce, and B. Rennick. Renal tubular transport and metabolism of organic cations by the rabbit. Am. J. Physiol. 241:F308-F314 (1981).
212. F. Roch-Ramel, K. Besseghir, and H. Murer. Renal excretion and tubular transport of organic anions and cations. In E. E. Windhager (ed.), Handbook of Physiology, Oxford University Press, New York Oxford, 1992, pp. 2189-2262.
213. K. J. Ullrich. Specificity of transporters for 'organic anions' and 'organic cations' in the kidney. Biochim. Biophys. Acta 1197:45-62 (1994).
214. L. T. Y. Wong, M. R. Escobar, D. D. Smyth, and D. S. Sitar. Gender-associated differences in rat renal tubular amantadine transport and absence of stereoselective transport inhibition by quinine and quinidine in distal tubules. J. Pharmacol. Exp. Ther. 267:1440-1444 (1993).
215. M. R. Escobar and D. S. Sitar. Site-selective effect of bicarbonate on amantadine renal transport: quinine-sensitive in proximal vs quinidine-sensitive sites in distal tubules. J. Pharmacol. Exp. Ther. 273:72-79 (1995).
216. H. Koepsell, V. Gorboulev, and P. Arndt. Molecular pharmacology of organic cation transporters in kidney. J. Membr. Biol. 167:103-117 (1999).
217. W. M. Barendt and S. H. Wright. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J. Biol. Chem. 277:22491-22496 (2002).
218. S. H. Cha, T. Sekine, J.-I. Fukushima, Y. Kanai, Y. Kobayashi, T. Goya, and H. Endou. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. 59:1277-1286 (2001).
219. S. Gluck and R. Nelson. The role of the V-ATPase in renal epithelial H+ transport. J. Exp. Biol. 172:205-218 (1992).
220. A. Somogyi, A. McLean, and B. Heinzow. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur. J. Clin. Pharmacol. 25:339-345 (1983).
221. A. Somogyi and B. Heinzow. Cimetidine reduces procainamide elimination. N. Engl. J. Med. 307:1080 (1982).
222. M. B. Davidson and A. L. Peters. An overview of metformin in the treatment of type 2 diabetes mellitus. Am. J. Med. 102:99-110 (1997).
223. J. E. Nestler. Metformin and the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 86:1430 (2001).
224. E. M. Velazquez, S. Mendoza, T. Hamer, F. Sosa, and C. J. Glueck. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43:647-654 (1994).
225. G. Horvath, N. Schmid, M. A. Fragoso, A. Schmid, G. E. Conner, M. Salathe, and A. Wanner. Epithelial organic cation transporters ensure pH dependent drug absorption in the airway. Am. J. Respir. Cell Mol. Biol. PMID: 16917073 (2006).
226. K. S. Lips, A. Lührmann, T. Tschernig, T. Stoeger, F. Alessandrini, V. Grau, R. V. Haberberger, H. Koepsell, R. Pabst, and W. Kummer. Down-regulation of the non-neuronal cholinergic system in acute allergic airway inflammation of rat and mouse, Life Sci., DOI 10.1016/j.lfs.2007.01.026
227. K. Kitaichi, M. Fukuda, H. Nakayama, N. Aoyama, Y. Ito, Y. Fujimoto, K. Takagi, K. Takagi, and T. Hasegawa. Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice. Neurosci. Lett. 382:195-200 (2005).
228. N. Feng, B. Mo, P. L. Johnson, M. Orchinik, C. A. Lowry, and K. J. Renner. Local inhibition of organic cation transporters increases extracellular serotonin in the medial hypothalamus. Brain Res. 1063:69-76 (2005).
229. F. H. Falcone, H. Haas, and B. F. Gibbs. The human basophil: a new appreciation of its role in immune responses. Blood 96:4028-4038 (2000).
230. S. Corbel, E. Schneider, F. M. Lemoine, and M. Dy. Murine hematopoietic progenitors are capable of both histamine synthesis and uptake. Blood 86:531-539 (1995).
231. M. Ogasawara, K. Yamauchi, Y.-i. Satoh, R. Yamaji, K. Inui, J. W. Jonker, A. H. Schinkel, and K. Maeyama. Recent advances in molecular pharmacology of the histamine systems: organic cation transporters as a histamine transporter and histamine metabolism. J. Pharmacol. Sci. 101:24-30 (2006).
232. A. Yonezawa, S. Masuda, K. Nishihara, I. Yano, T. Katsura, and K.-i. Inui. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem. Pharmacol. 70:1823-1831 (2005).
233. A. Yonezawa, S. Masuda, S. Yokoo, T. Katsura, and K.-i. Inui. Cisplatin and oxaliplatin, but not nedaplatin, are substrates of human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family. J. Pharmacol. Ex. Ther. 319:879-886 (2006).
234. O. Briz, M. A. Serrano, N. Rebollo, B. Hagenbuch, P. J. Meier, H. Koepsell, and J. J. G. Marin. Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol. Pharmacol. 61:853-860 (2002).